PD-L1 Testing in Urothelial Carcinoma: Analysis of a Series of 1401 Cases Using Both the 22C3 and SP142 Assays

Overview of attention for article published in Pathology & Oncology Research, April 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 1,344 followers.

RT @karenmac9: Shout out to all those staff in Molecular Pathology ⁦@qehbham⁩ contributing to paper below. PD-L1 Testing in Urothelial Carc…

11 Apr 2022

Reply Repost Favourite

PD-L1 "positivity" is not a binary value; all PD-L1 CDx assays are clinically validated and are not interchangeable. Would be very cautious about using a LDT PD-L1 test as a surrogate to a CDx. https://t.co/LtovRnqILV

11 Apr 2022

Reply Repost Favourite

RT @karenmac9: Shout out to all those staff in Molecular Pathology ⁦@qehbham⁩ contributing to paper below. PD-L1 Testing in Urothelial Carc…

11 Apr 2022

Reply Repost Favourite

RT @karenmac9: Shout out to all those staff in Molecular Pathology ⁦@qehbham⁩ contributing to paper below. PD-L1 Testing in Urothelial Carc…

11 Apr 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.